Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study
Journal of Pediatric and Adolescent Gynecology · 2026
DOI: 10.1016/j.jpag.2026.02.008 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Pediatric and Adolescent Gynecology, 2026. Verfasst von Jessica Y Shim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Obstetrics, Gynecology and Reproducti…. Hauptthemen laut MEDLINE: Endometriosis, Hydrocarbons, Fluorinated, Pyrimidines. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
STUDY OBJECTIVE: To evaluate the efficacy and tolerability of the gonadotropin-releasing hormone antagonist elagolix for endometriosis-associated pain symptoms in adolescents and young adults (AYAs) METHODS: We performed a retrospective cohort study of AYAs with laparoscopically confirmed endometriosis prescribed elagolix between November 2018 and December 2024 at a pediatric tertiary care center. Data from the electronic medical record included demographic and clinical characteristics, previous hormonal therapies, elagolix dose and use of add-back therapy, symptom response, and adverse effects. Primary outcomes were patient-reported symptom improvement and treatment discontinuation. The study was deemed IRB exempt. RESULTS: Nineteen patients began taking elagolix, median age 18 years (IQR = 16-21). Endometriosis stage was I in 8 patients (42%), II in 10 (52%), and III in 1 (5%). All patients had previously tried 2 or more hormonal therapies, most commonly the levonorgestrel intrauterine device and norethindrone acetate (68% each). Of patients treated with elagolix, add-back therapy was used in 58%, primarily norethindrone acetate. Overall, 53% reported some improvement; dysmenorrhea and pelvic pain improved in 42% and 53%, respectively. Adverse events included persistent pelvic pain (37%), unpredictable bleeding (26%), and mood changes (16%). No serious adverse events occurred. Discontinuation occurred in 95% of patients, most commonly due to persistent pain and mood changes. The median treatment duration was 5.5 months (IQR = 3-12). CONCLUSION: In this small cohort, elagolix was associated with modest symptom improvement but high discontinuation rates in AYAs with endometriosis. Larger prospective studies are needed to define its role in the long-term management of adolescent endometriosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.
- Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts.
- Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts; Divison of…
- Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts. Electronic address: elizabeth.boskey@childrens.harv…
Zitieren
APA
Shim, J. Y., Scatoni, A., Laufer, M. R., & Boskey, E. R. (2026). Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study. Journal of Pediatric and Adolescent Gynecology. https://doi.org/10.1016/j.jpag.2026.02.008
Vancouver
Shim JY, Scatoni A, Laufer MR, Boskey ER. Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study. Journal of Pediatric and Adolescent Gynecology. 2026. doi:10.1016/j.jpag.2026.02.008
BibTeX
@article{Shim2026,
author = {Shim, Jessica Y and Scatoni, Ava and Laufer, Marc R and Boskey, Elizabeth R},
title = {Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study},
journal = {Journal of Pediatric and Adolescent Gynecology},
year = {2026},
doi = {10.1016/j.jpag.2026.02.008}
}
EUVIMED